EGFR and neoplasm: On theother hand, real-time targeted agent fluorescence demonstrated anincrease in both tumor and muscle tissues, failing to represent thereceptor-blocking process. The currentstudy did not employ commonly used monoclonal antibodies for treatingHNC and a wide range of other EGFR-positive cancer types., In future studies, FDA-approved cetuximab antibody therapy for EGFRinhibition in HNC will be employed to accurately recapitulate HNCtherapy.